Moreover, targeting CD39, the rate-limiting ecto-enzyme of the ATP-adenosine pathway, demonstrated more profound anti-tumor effects compared with antagonists that block other members of the adenosinergic family (e.g., CD73 and A2AR/A2BR) [9, 14, 26]. Here, ENTPD1 is linked to neoplasm.